532
Views
19
CrossRef citations to date
0
Altmetric
Review Article

Multifunctional nanoparticles for targeting cancer and inflammatory diseases

, , &
Pages 888-903 | Received 09 Jun 2013, Accepted 04 Aug 2013, Published online: 12 Sep 2013
 

Abstract

The interplay between cancer and inflammation has been well documented over the years and the role of nanomedical technologies for treating both these diseases has become evident over the past few decades. With the advances in nanoparticle-based imaging and therapeutic platforms that can exploit the pathological conditions of the tumor and the inflamed sites to effectively deliver drugs, genes and imaging/contrast agents; the management of such conditions with favorable therapeutic outcomes seems plausible. This review will summarize some of the latest advances in the field of targeted nanomedicine development to combat cancer and inflammation. Illustrative examples of multifunctional-targeted nanosystems are presented that highlight their potential in delivering diverse payloads, including small molecule drugs, nucleic acids and imaging agents for simultaneous theranostic interventions.

Notes

*Review article contributed to the special issue of the “Journal of Drug Targeting” honoring Prof. Vladimir Torchilin with the 2013 Journal Drug Targeting’s Lifetime Achievement Award. Guest Editor: Prof. Mansoor M. Amiji.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.